Wells Fargo’s Metagenomi Therapeutics MGX Stock Holding History

Wells Fargo’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$271K	Buy	202,138 +83,728	+71%	+$130K	﹤0.01%	4516
2025 Q4	$192K	Buy	118,410 +16,402	+16%	+$35.5K	﹤0.01%	5093
2025 Q3	$242K	Buy	102,008 +3,612	+4%	+$7.33K	﹤0.01%	4827
2025 Q2	$146K	Sell	98,396 -11,572	-11%	-$18.1K	﹤0.01%	4957
2025 Q1	$150K	Buy	109,968 +14,780	+16%	+$35.2K	﹤0.01%	4871
2024 Q4	$344K	Buy	95,188 +33,582	+55%	+$81K	﹤0.01%	4438
2024 Q3	$134K	Buy	61,606 +35,294	+134%	+$122K	﹤0.01%	4844
2024 Q2	$107K	Buy	26,312 +1,418	+6%	+$9.74K	﹤0.01%	4894
2024 Q1	$263K	Buy	+24,894	New	+$286K	﹤0.01%	4297

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo's MGX Position: Q1 2026 in Review

Wells Fargo increased its Metagenomi Therapeutics (MGX) stake by 71% in Q1 2026, buying an estimated $130K and bringing the position to 202,138 shares worth $271K. The position accounts for ﹤0.01% of the portfolio, ranked #4516.

Wells Fargo first reported a position in MGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $344K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Wells Fargo held 202,138 shares of Metagenomi Therapeutics worth $271K as of Q1 2026.
Wells Fargo bought 83,728 Metagenomi Therapeutics shares in Q1 2026, an estimated $130K.
Metagenomi Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4516 holding.
Wells Fargo first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 9 quarters since.
Wells Fargo's Metagenomi Therapeutics position peaked at $344K in Q4 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.